Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study Using Genz-644470 and Sevelamer Carbonate in Hyperphosphatemic Chronic Kidney Disease Patients on Hemodialysis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 May 2015
Price :
$35
*
At a glance
- Drugs Genz 644470 (Primary) ; Sevelamer
- Indications Hyperphosphataemia
- Focus Therapeutic Use
- Acronyms LEAP
- Sponsors Genzyme Corporation; Sanofi
- 09 May 2014 New trial record